Detection and preliminary characterization of CD8+T lymphocytes specific for Wilms’ tumor antigen in patients with non-Hodgkin lymphoma

References

• Leukemia and Lymphoma Society. Fighting blood cancers. Facts 2012. Available from: www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/generalcancer/pdf/facts.pdf
   Google Scholar
• Brody J, Levy R. Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant. Immunotherapy 2009;1:809–824.
   PubMed Web of Science ®Google Scholar
• Inoges S, de Cerio AL, Soria E, et al. Idiotype vaccines for human B-cell malignancies. Curr Pharm Des 2010;16:300–307.
   PubMed Web of Science ®Google Scholar
• Reddy SA, Okada C, Wong C, et al. T cell antigen receptor vaccines for active therapy of T cell malignancies. Ann NY Acad Sci 2001;941:97–105.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15:5323–5337.
   PubMed Web of Science ®Google Scholar
• Cilloni D, Gottardi E, De Micheli D, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002;16:2115–2121.
   PubMed Web of Science ®Google Scholar
• Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071–3079.
   PubMed Web of Science ®Google Scholar
• Ogawa H, Tamaki H, Ikegame K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003;101:1698–1704.
   PubMed Web of Science ®Google Scholar
• Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999;13:393–399.
   PubMed Web of Science ®Google Scholar
• Candoni A, Tiribelli M, Toffoletti E, et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol 2009;82:61–68.
   PubMed Web of Science ®Google Scholar
• Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009; 27:5195–5201.
   PubMed Web of Science ®Google Scholar
• Lange T, Hubmann M, Burkhardt R, et al. Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia 2011; 25:498–505.
   PubMed Web of Science ®Google Scholar
• Drakos E, Rassidakis GZ, Tsioli P, et al. Differential expression of WT1 gene product in non-Hodgkin lymphomas. Appl Immunohistochem Mol Morphol 2005;13:132–137.
   PubMedGoogle Scholar
• Perotti D, Mondini P, Giardini R, et al. No evidence of WT1 involvement in a Burkitt's lymphoma in a patient with Denys-Drash syndrome. Ann Oncol 1998;9:627–631.
   PubMed Web of Science ®Google Scholar
• Huang WT, Huang CC, Weng SW, et al. Expression of the multidrug resistance protein MRP and the lung-resistance protein LRP in nasal NK/T cell lymphoma: further exploring the role of P53 and WT1 gene. Pathology 2009;41:127–132.
   PubMed Web of Science ®Google Scholar
• Menssen A, Vollmer S, Trommler P, et al. Analysis of the TCRBV repertoire of T cells in normal, human skin: evidence for a restricted diversity. J Invest Dermatol 2000;115:66–73.
   PubMed Web of Science ®Google Scholar
• Wolfl M, Kuball J, Eyrich M, et al. Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities. Cytometry A 2008;73:1043–1049.
   PubMed Web of Science ®Google Scholar
• Wolfl M, Kuball J, Ho WY, et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007;110:201–210.
   PubMed Web of Science ®Google Scholar
• Ishizaki H, Manuel ER, Song GY, et al. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol Immunother 2011;60:99–109.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Zhou W, Lacey SF, et al. Programmed death-1 receptor and interleukin-10 in liver transplant recipients at high risk for late cytomegalovirus disease. Transpl Infect Dis 2010;12: 363–370.
   PubMed Web of Science ®Google Scholar
• Currier JR, Kuta EG, Turk E, et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002;260:157–172.
   PubMed Web of Science ®Google Scholar
• Diamond DJ, York J, Sun JY, et al. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997;90:1751–1767.
   PubMed Web of Science ®Google Scholar
• La Rosa C, Wang Z, Lacey SF, et al. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara. Exp Hematol 2006;34:497–507.
   PubMed Web of Science ®Google Scholar
• Zhou W, Longmate J, Lacey SF, et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood 2009;113:6465–6476.
   PubMed Web of Science ®Google Scholar
• Rezvani K, Grube M, Brenchley JM, et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003;102: 2892–2900.
   PubMed Web of Science ®Google Scholar
• Rezvani K, Yong AS, Tawab A, et al. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 2009;113:2245–2255.
   PubMed Web of Science ®Google Scholar
• van Baren N, Chambost H, Ferrant A, et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 1998; 102:1376–1379.
   PubMed Web of Science ®Google Scholar
• Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96:1921–1925.
   PubMed Web of Science ®Google Scholar
• Cong XL, Han ZC. Survivin and leukemia. Int J Hematol 2004; 80:232–238.
   PubMed Web of Science ®Google Scholar
• Salter RD, Howell DN, Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 1985;21:235–246.
   PubMed Web of Science ®Google Scholar
• Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008;111:236–242.
   PubMed Web of Science ®Google Scholar
• Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009;113: 6541–6548.
   PubMed Web of Science ®Google Scholar
• Buckler AJ, Pelletier J, Haber DA, et al. Isolation, characterization, and expression of the murine Wilms’ tumor gene (WT1) during kidney development. Mol Cell Biol 1991;11:1707–1712.
   PubMed Web of Science ®Google Scholar
• Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. Annu Rev Immunol 2003;21:139–176.
   PubMed Web of Science ®Google Scholar
• Provasi E, Genovese P, Lombardo A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med 2012;18:807–815.
   PubMed Web of Science ®Google Scholar
• Rezvani K, Brenchley JM, Price DA, et al. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms’ tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res 2005;11:8799–8807.
   PubMed Web of Science ®Google Scholar
• Manuel ER, Blache CA, Paquette R, et al. Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors. Cancer Res 2011;71:4183–4191.
   PubMed Web of Science ®Google Scholar
• Xue SA, Gao L, Hart D, et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 2005;106:3062–3067.
   PubMed Web of Science ®Google Scholar
• Kuball J, Dossett ML, Wolfl M, et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007;109:2331–2338.
   PubMed Web of Science ®Google Scholar
• Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol 2002;2:512–519.
   PubMed Web of Science ®Google Scholar
• Grigg A, Ritchie D. Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant 2004;10:579–590.
   PubMed Web of Science ®Google Scholar
• Wahlin BE, Sander B, Christensson B, et al. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007;13:388–397.
   PubMed Web of Science ®Google Scholar
• Rezvani K, Yong AS, Savani BN, et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007;110:1924–1932.
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004;101:13885–13890.
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Murakami M, et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 2003;78:56–61.
   PubMed Web of Science ®Google Scholar
• Tsuboi A, Oka Y, Osaki T, et al. WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases. Microbiol Immunol 2004;48:175–184.
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010;107:13824–13829.
   PubMed Web of Science ®Google Scholar